RxDoctor Payments Data

Eric Bernstein, MD

Family Medicine · San Antonio, TXNPI 1508978487

Payments from drug & device makers

$12,249in general payments, 2019–2025

Across 787 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Amgen$794
  • Pfizer$663
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$12,231100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,249 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$460,206
Medicare patients
726
Services billed
9,564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$116,595
Synjardy XrEmpagliflozin/Metformin Hcl31$45,951
TrulicityDulaglutide24$40,947
JardianceEmpagliflozin33$40,640
XareltoRivaroxaban19$24,108
Janumet XrSitagliptin Phos/Metformin Hcl27$22,481
FarxigaDapagliflozin Propanediol17$20,424
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$19,156
JanuviaSitagliptin Phosphate18$16,070
Tresiba Flextouch U-200Insulin Degludec18$15,953
Xigduo XrDapaglifloz Propaned/Metformin15$15,133
MounjaroTirzepatide14$14,603
EliquisApixaban12$14,492
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$11,770
Repatha SureclickEvolocumab11$8,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,795$116,59575 claims
Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy$75$94,89975 claims
Lilly USA, LLCTrulicity, Mounjaro$1,035$55,55038 claims
MerckJanumet Xr, Januvia$544$38,55145 claims
AstraZenecaFarxiga, Symbicort$1,274$27,52441 claims
Johnson & JohnsonXarelto$213$24,10819 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$458$19,18839 claims
PfizerEliquis$663$14,49212 claims
AbbVieLinzess, Synthroid$2,398$10,23678 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →